Medicare Submission for Pre-Approval in Clinical Research Ronda Sharp, R.N., B.S.N., C.C.R.C. Clinical Research Facilitator Methodist Research Institute.

Slides:



Advertisements
Similar presentations
Investigational Device Exemption (IDE) Overview for IRBs
Advertisements

Investigational Device Exemptions (IDE) CFR Title 21, Part 812
Overview of FDA Device Regulations
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Exempt Research Mary Banks BS, BSN IRB Director CRC IRB and BUMC IRB.
Columbia University Medical Center Research Billing Compliance presented by Office for Billing Compliance Research Billing Compliance presented by Office.
Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.
Medical Devices Approval Process
©2012 PhramaSeek Financial Services, LLC Navigating Medicare Billing Guidelines in Clinical Trials.
Introduction to Vocational Rehabilitation for Medical Providers.
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
How to Obtain Institutional Review Board (IRB) Approval Richard Wagner Associate Director UCSF Human Research Protection Program August 14, 2008.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Foundation Financial Services Post Award Nancy Gomez Post Award Analyst.
NATIONAL CLINICAL TRIAL (NCT) NUMBER Clinical Trials Management Office December 17, 2014.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
CPSP Application Overview Candice Zimmerman, CPSP Manager Lorraine Cardenas, Program Analyst November 2, 2011.
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
John E. Steiner, Jr., Esq Chief Compliance Officer Cleveland Clinic Health System Cleveland, Ohio Coverage and Billing Issues for Clinical Research The.
New Faculty Orientation August 22, 2012 UAMS Research Support Center Director: Tom Wells (501)
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Office of Clinical Research and Innovative Care Compliance (OCRICC) What You Need To Know About Conducting Research at Froedtert Hospital Roberta Navarro,
DCB New Grantee Workshop: Post-Award Administration of Grants Brett Hodgkins Team Leader National Cancer Institute Office of Grants Administration.
Conflict of Interest Policy Implementation October 23, 2014.
Medical Devices IRB Determination IRB Member Continuing Education.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
FDA Focus On Consumer Protection
Physician Lunch-N-Learn – PECOS Registration Training Getting Started with PECOS for Physicians June 15, 2010.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Draft Model Manufacturer Agreement Medicare Coverage Gap Discount Program Public Meeting June 1, 2010.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Melissa McCarey, MPH Jefferson Clinical Research Institute (JCRI) Clinicaltrials.gov: What is it? What do I need to know?
Business Operations Pre-Award. What is required to begin the business process? Possible indicators CDA executed Cancer Center MDG/PRC approvals Department.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Fully accredited since 2006 Tom Conquergood, CIP Working with Quorum October 13, 2015 Thomas Jefferson University.
Welcome New IRB Member! This brief presentation covers: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
FDA Regulation: The Impact on Product Development and Reporting Monica Graves Director – Marketing Operations Oversight RAI Services Company May 18, 2009.
Ensures that studies are billed for research specific procedures.
HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.
Business Operations Pre-Award. Confidential Disclosure Agreements (CDA)/ Non-Disclosure Agreements (NDA)
IRB Presentation to the Pediatric Ethics Subcommittee of the FDA regarding “Gonadotropin Releasing Hormone (GnRH) Agonist Test in Disorders of Puberty”
DMC Research Compliance Our mission is to assure that all research at the DMC is ethical, safe and compliant with regulatory standards; and to support.
Click to begin. Click here for Bonus round OIG Issues Medicare & Medicaid General 100 Point 200 Points 300 Points 400 Points 500 Points 100 Point 200.
Clinical Trial Billing and Patient Remuneration
What Are the FDA Requirements for Submitting an IDE?
Division of Cardiovascular Devices
Premarket Notification 510(k) process
Investigator of Record – Definition
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
First-in-Man, First In The USA: What’s The Difference?
Electronic Data Interchange (EDI)
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Bozeman Health Clinical Research
Investigator of Record – Definition
Investigator of Record – Definition
Expedited Status Update January 14, 2019
Presentation transcript:

Medicare Submission for Pre-Approval in Clinical Research Ronda Sharp, R.N., B.S.N., C.C.R.C. Clinical Research Facilitator Methodist Research Institute

History of Pre-Approval Process At Methodist Research Institute, we have been submitting for pre-approval for IDE trials since The process has evolved from sending in 2- 3” binders of information to CMS on every IDE trial to a very streamlined process. The timeframe for pre-approval has decreased from 2-3 months to a matter of 2-3 weeks.

Goal of Pre-Approval Process To provide CMS with information about specific IDE clinical trials to assure reimbursement for Standard of Care Services for subjects enrolled in these trials. To comply with CMS guidelines.

IDE IDE- Investigational Device Exemption

IDE Classification Eligible for Pre- Approval Category B Certain Category A

Definition of Category B Device Non-experimental/ Investigational Devices, regardless of classification, under investigation to establish substantial equivalence to previously/ currently legally marketed device, or Class III devices whose technological characteristics and indications for use are comparable to a PMA-approved device, or Class III devices with technological advances compared to a PMA-approved device (generational changes), or Class III devices that are comparable to a PMA-approved device which are under investigation for a new indication for use. No significant modifications to the device were required, or

Definition of Category B Device Non-experimental/ Investigational Class III devices that become the subject of an IDE after FDA requires pre-market approval (no PMA was submitted or the PMA was denied), or Non-significant risk device investigations for which FDA required the submission of an IDE.

Definition of Category A Device Experimental Class III devices of a type for which no marketing application has been approved through the pre- market approval (PMA process for any indication for use. Class III devices that would otherwise be in Category B but have undergone significant modification for a new indication for use.

CMS Centers for Medicare and Medicaid Services

Divisions of CMS Part A- Inpatient Services Part B- Physician and Outpatient Services

Submission Requirements Provider name and number (for Part A it would be the institution name and number, for Part B it would be the PI provider number along with the mailing address) For Part B, all co-investigators that will bill for services must also be listed with the submission.

Submission Requirements (continued) Name and Number of the investigational device(s) utilized in the trial. A narrative description of the device(s).

Submission requirements (continued) Signed copy of the FDA-approval letter demonstrating category A or B IDE status. The FDA letter containing the most current approved number of institutions and subjects (may be 2 separate letters).

Submission Requirements (continued) Number of Medicare cases planned for the study at the specific institution. A copy of the final protocol from the sponsor.

Additional items to be maintained at the site and readily available The agreement between the company or manufacturer and the provider, furnishing the details of the provider participation. At least 2 peer-review publications. Any product literature illustrating the device and/or procedure. IRB-approval for the protocol to be carried out at the institution.

Medicare Part A Intermediary Richard Baer, M.D. Medical Director AdminaStar Federal 255 N. Michigan Ave. 22 nd Floor AFCH-85 Chicago, IL (312)

Medicare Part B Intermediary Carolyn Cunningham, M.D. Medical Director AdminaStar Federal 8115 Knue Rd.- AF10 Indianapolis, IN (317)

CMS Website

Questions? If there are any unanswered questions, I will go to the appropriate person to obtain the answer. My address: